Payment overview · 2025
General Payments
$13,931.33
29 reported records · 8 companies
Healthcare provider profile · identity verified
Jacqueline M Champlain, MD
Allopathic & Osteopathic Physicians|Family Medicine · ELGIN, TX · NPI 1497049209
Verified facts
What the public records show
CMS Open Payments records show Jacqueline M Champlain, MD received $13,931.33 in general payments during 2025 across 29 reported records.
Novo Nordisk Inc accounted for 98.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rybelsus.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13,730.64 | 98.6% | 19 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $91.52 | 0.7% | 4 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $24.00 | 0.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.85 | 0.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.67 | 0.1% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.36 | 0.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.93 | 0.1% | 1 | 2025 |
| MILLICENT US INC | Unresolved — no canonical attribution shown | $14.36 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $11,147.00 | 5 |
| Travel and Lodging | $2,019.90 | 6 |
| Food and Beverage | $764.43 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13,663.25 | 15 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $91.52 | 4 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $24.00 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.71 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.67 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.93 | 1 | 2025 |
Source payment records
|
|||||
| FEMLYV Normalized: femlyv |
Drug | MILLICENT US INC | $14.36 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $9.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 150 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 110 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
150 | 47 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
150 | 47 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
121 | 31 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
110 | 33 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 485 | 194 |
| Gabapentin | Gabapentin | 301 | 115 |
| Lisinopril | Lisinopril | 272 | 98 |
| Levothyroxine Sodium | Levothyroxine Sodium | 258 | 103 |
| Amlodipine Besylate | Amlodipine Besylate | 215 | 87 |
| Montelukast Sodium | Montelukast Sodium | 195 | 63 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 192 | 73 |
| Pantoprazole Sodium | Pantoprazole Sodium | 191 | 83 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 187 | 39 |
| Omeprazole | Omeprazole | 179 | 76 |
| Losartan Potassium | Losartan Potassium | 175 | 77 |
| Metformin Hcl Er | Metformin Hcl | 175 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 175 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 158 | 63 |
| Jardiance | Empagliflozin | 150 | 47 |
| Furosemide | Furosemide | 137 | 58 |
| Meloxicam | Meloxicam | 137 | 54 |
| Trulicity | Dulaglutide | 121 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 113 | 39 |
| Ozempic | Semaglutide | 110 | 33 |
| Potassium Chloride | Potassium Chloride | 110 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 108 | 45 |
| Metformin Hcl | Metformin Hcl | 100 | 44 |
| Allopurinol | Allopurinol | 98 | 33 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 96 | 36 |
| Trazodone Hcl | Trazodone Hcl | 94 | 34 |
| Eliquis | Apixaban | 87 | 26 |
| Sertraline Hcl | Sertraline Hcl | 87 | 26 |
| Cefdinir | Cefdinir | 80 | 65 |
| Duloxetine Hcl | Duloxetine Hcl | 77 | 26 |
| Glipizide Er | Glipizide | 75 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 73 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 72 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 70 | 34 |
| Alendronate Sodium | Alendronate Sodium | 69 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 66 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 66 | 22 |
| Simvastatin | Simvastatin | 66 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 63 | 45 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 63 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 60 | 41 |
| Tramadol Hcl | Tramadol Hcl | 60 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 57 | 23 |
| Clonazepam | Clonazepam | 56 | 12 |
| Ondansetron Odt | Ondansetron | 56 | 29 |
| Carvedilol | Carvedilol | 55 | 23 |
| Donepezil Hcl | Donepezil Hcl | 54 | 20 |
| Eszopiclone | Eszopiclone | 54 | 19 |
| Glipizide | Glipizide | 52 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 50 | 22 |
| Januvia | Sitagliptin Phosphate | 50 | 11 |
| Pregabalin | Pregabalin | 49 | 22 |
| Fluconazole | Fluconazole | 48 | 39 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 47 | 17 |
| Bupropion Xl | Bupropion Hcl | 46 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | 17 |
| Famotidine | Famotidine | 45 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 44 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 41 | 31 |
| Nystatin | Nystatin | 40 | 20 |
| Valsartan | Valsartan | 39 | 15 |
| Clonidine Hcl | Clonidine Hcl | 38 | 19 |
| Colchicine | Colchicine | 38 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | 13 |
| Terbinafine Hcl | Terbinafine Hcl | 38 | 22 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 37 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 37 | 13 |
| Prednisone | Prednisone | 37 | 19 |
| Spironolactone | Spironolactone | 37 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 35 |
| Azithromycin | Azithromycin | 35 | 31 |
| Ezetimibe | Ezetimibe | 34 | 12 |
| Entresto | Sacubitril/Valsartan | 33 | suppressed |
| Alprazolam | Alprazolam | 32 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | 14 |
| Estradiol | Estradiol | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 29 | 13 |
| Ketoconazole | Ketoconazole | 29 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Etodolac | Etodolac | 28 | suppressed |
| Ibuprofen | Ibuprofen | 28 | suppressed |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 27 | suppressed |
| Glimepiride | Glimepiride | 27 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | 15 |
| Tresiba Flextouch U-200 | Insulin Degludec | 25 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Naproxen | Naproxen | 22 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 21 | 20 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | 11 |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 18 |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | 14 |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 19 | 17 |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | 14 |
| Diazepam | Diazepam | 18 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 17 |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Indomethacin | Indomethacin | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Dexamethasone | Dexamethasone | 15 | 14 |
| Linzess | Linaclotide | 15 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | 13 |
| Rybelsus | Semaglutide | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Mupirocin | Mupirocin | 14 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Incontrol Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $13,931.33 · 29 records | Novo Nordisk Inc | APTIMA, Cologuard Collection Kit, FEMLYV, JARDIANCE, Kerendia, Ozempic, Rybelsus, Wegovy, ZORYVE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error